– GETTY IMAGES/ISTOCKPHOTO / PALMIHELP – Archivo
MADRID 20 Mar. (EUROPA PRESS) –
The director of the One Oncology Madrid-Grupo Quirónsalud program and head of the Medical Oncology Service at Hospital Ruber Internacional, Enrique Grande, has highlighted that radiometabolic theragnosis represents one of the most relevant advances in recent years in the treatment of advanced prostate cancer and neuroendocrine tumors.
“It allows targeted therapies to be administered with great precision based on information previously obtained through advanced molecular imaging techniques such as PET-CT,” explained the specialist.
Thus, it indicates that patients with prostate and neuroendocrine tumors can benefit from this type of therapies that combine an accurate diagnosis with a targeted treatment with fewer side effects.
In this sense, Grande has detailed that One Oncology Madrid-Grupo Quirónsalud has worked to guarantee that all patients of the Quirónsalud group in Madrid who express certain markers in the PET-CT test can access this type of innovative treatments, especially those with metastatic prostate cancer in which conventional hormonal treatments are no longer effective.
Furthermore, he emphasizes that this approach offers important clinical advantages: “On the one hand, in many cases it represents an alternative to traditional chemotherapy, which usually generates great concern in patients; on the other, it allows us to better select those patients with a greater probability of responding thanks to the information provided by PSMA PET-CT.”
Quirónsalud’s private hospitals in Madrid have three PET-CT and two SPECT-CT machines, as well as facilities for the in-hospital administration of these radiometabolic treatments, and can treat up to 500 patients per year. “In our hospital network we have two specific rooms for theragnosis that meet the requirements demanded by the Nuclear Safety Council for the administration of radiometabolic therapy, leading those existing in the private sector of the Community of Madrid,” reported Antonio Maldonado, head of the Nuclear Medicine Service at the Quirónsalud Madrid University Hospital and La Luz University Hospital.